Trial · NCT01672879
Adverse events980
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 980
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Blinded Phase: SIM 200 mg | 10 | 87 | |
| other | Anaemia | Blood and lymphatic system disorders | Blinded Phase: SIM 700 mg | 7 | 86 | |
| other | Anaemia | Blood and lymphatic system disorders | Blinded Phase: Placebo | 6 | 85 | |
| other | Anaemia | Blood and lymphatic system disorders | Open-Label Phase: SIM 700 mg | 3 | 40 | |
| other | Splenomegaly | Blood and lymphatic system disorders | Blinded Phase: SIM 200 mg | 3 | 87 | |
| other | Splenomegaly | Blood and lymphatic system disorders | Blinded Phase: SIM 700 mg | 4 | 86 | |
| other | Splenomegaly | Blood and lymphatic system disorders | Blinded Phase: Placebo | 6 | 85 | |
| other | Splenomegaly | Blood and lymphatic system disorders | Open-Label Phase: SIM 700 mg | 0 | 40 | |
| other | Palpitations | Cardiac disorders | Blinded Phase: SIM 200 mg | 6 | 87 | |
| other | Palpitations | Cardiac disorders | Blinded Phase: SIM 700 mg | 1 | 86 | |
| other | Palpitations | Cardiac disorders | Blinded Phase: Placebo | 3 | 85 | |
| other | Palpitations | Cardiac disorders | Open-Label Phase: SIM 700 mg | 0 | 40 | |
| other | Vertigo | Ear and labyrinth disorders | Blinded Phase: SIM 200 mg | 4 | 87 | |
| other | Vertigo | Ear and labyrinth disorders | Blinded Phase: SIM 700 mg | 6 | 86 | |
| other | Vertigo | Ear and labyrinth disorders | Blinded Phase: Placebo | 5 | 85 | |
| other | Vertigo | Ear and labyrinth disorders | Open-Label Phase: SIM 700 mg | 0 | 40 | |
| other | Abdominal distension | Gastrointestinal disorders | Blinded Phase: SIM 200 mg | 9 | 87 | |
| other | Abdominal distension | Gastrointestinal disorders | Blinded Phase: SIM 700 mg | 10 | 86 | |
| other | Abdominal distension | Gastrointestinal disorders | Blinded Phase: Placebo | 9 | 85 | |
| other | Abdominal distension | Gastrointestinal disorders | Open-Label Phase: SIM 700 mg | 4 | 40 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01672879/events